Sanofi-aventis

FDA approves new treatment for advanced colorectal cancer

Friday, September 28, 2012 12:19 PM

The FDA has approved Bayer’s and Onyx Pharmaceuticals’ Stivarga (regorafenib) to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body.

More... »

FDA approves Zaltrap for metastatic colorectal cancer

Monday, August 6, 2012 12:51 PM

The FDA has approved Sanofi-Aventis’ Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

More... »

Rosenberg joins Esperion Therapeutics as CMO

Monday, April 9, 2012 02:56 PM

Esperion Therapeutics, a Plythmouth, Michigan-based company that discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases, has appointed Noah Rosenberg, MD, as its chief medical officer.

More... »

Premier Research names Drouet executive director, Oncology Europe

Monday, January 23, 2012 12:36 PM

Premier Research Group has appointed Etienne Drouet executive director, Oncology Europe. Drouet will play a leading role in the operations, strategic planning and corporate development of Premier Research’s growing portfolio of oncology businesses.

More... »

Immune Design, Sanofi collaborate in allergy research

Wednesday, October 26, 2011 10:39 AM

Immune Design has entered into an early-stage research collaboration with Sanofi-Aventis to investigate the use of IDC's Glucopyranosyl Lipid Adjuvant (GLA) technology, a toll–like receptor 4 (TLR-4) agonist, in the field of allergy.

More... »

Sanofi-Aventis changes name

Monday, May 9, 2011 01:01 PM

Sanofi-Aventis will change the company’s name to just Sanofi, immediately, according to Pharma Times.

More... »

Bayer CEO considers merger only if stars are aligned

Thursday, May 5, 2011 12:40 PM

German-based Bayer is open to a “merger of equals” that would enhance its health-care unit without paying a premium for an acquisition, says Bayer’s chief executive officer Marijn Dekkers, according to a Bloomberg report.

More... »

Sanofi, Regeneron show positive results for Zaltrap

Wednesday, April 27, 2011 02:13 PM

Partners Sanofi-Aventis and Regeneron Pharmaceuticals report positive results for a late stage study evaluating Zaltrap (aflibercept), a colorectal cancer candidate.  

More... »

Sanofi-aventis collaborates with Stanford University

Monday, April 18, 2011 12:49 PM

Sanofi-aventis has entered into a research collaboration agreement that will last several years through the Stanford University Bio-X program, according to Fierce Biotech.  The Stanford program supports, organizes, and facilitates interdisciplinary, collaborative and innovative research projects in the early phases of development.

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »